Description: CNQX (FG9065;FG-9065; 6-cyano-7-nitroquinoxaline-2,3-dione) is an AMPA/kainate antagonist that inhibits AMPA and kainate receptors with IC50 values of 0.3 μM, 1.5 μM, respectively. CNQX is also an antagonist at the glycine modulatory site on the NMDA receptor complex with an IC50 of 25 μM). CNQX can be used to isolate GABAA receptor mediated spontaneous inhibitory postsynaptic currents and antagonizes non-NMDA receptor-mediated responses in cultured cerebellar granule cells. CNQX shows neuroprotective effects in models of ischemia and inhibits seizure-like activity in hippocampal neurons.

References:

[1]. Quinoxalinediones: Potent Competitive non-NMDA Glutamate Receptor Antagonists. Science. 1988 Aug 5;241(4866):701-3.

[2]. Blockade of excitatory synaptic transmission by 6-cyano-7-nitroquinoxaline-2,3-dione(CNQX) in the hippocampus in vitro. Neurosci Lett. 1988 Sep 23;92(1):64-8.

[3]. CNQX and DNQX block non-NMDA synaptic transmission but not NMDA-evoked locomotion in lamprey spinal cord. Brain Res. 1990 Jan 8;506(2):297-302.

[4]. Attenuation of Cocaine-Seeking Behaviour by the AMPA/kainate Receptor Antagonist CNQX in Rats. Psychopharmacology (Berl). 2003 Feb;166(1):69-76.

[5]. Infusion of the non-NMDA receptor antagonist CNQX into the amygdala blocks the expression of fear-potentiated startle. Behav Neural Biol. 1993 Jan;59(1):5-8.

Related CAS: 479347-85-8 (disodium salt)

纯度：≥98%

CAS：115066-14-3